493
edits
Changes
Update perm redirect.
Line 89:
Line 89:
Corcoran NM et al. 2010b. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 103:462-8. PMID 20648008
Corcoran NM et al. 2010b. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 103:462-8. PMID 20648008
−Mandvi, A. A Simple Plot. The Daily Show with Jon Stewart, aired June 14, 2012. http://www.cc.com/video-clips/jucn2a/the-daily-show-with-jon-stewart-a-simple-plot
+Mandvi, A. A Simple Plot. The Daily Show with Jon Stewart, aired June 14, 2012. https://www.cc.com/video/jucn2a/the-daily-show-with-jon-stewart-a-simple-plot
Reid ME et al. 2004 A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74 PMID 15487766
Reid ME et al. 2004 A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74 PMID 15487766
van Eersel J et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. PNAS 107:13888-93. PMID 20643941
van Eersel J et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. PNAS 107:13888-93. PMID 20643941